India, Aug. 12 -- Sellas Life Sciences Group, Inc. (SLS) a late-stage clinical biopharmaceutical company, released financial results for the second quarter ended June 30, 2026, reporting a wider loss than a year ago, driven by higher operating expenses.
Company Profile
Sellas is focused on developing therapies for cancer, with programs targeting hematologic malignancies and solid tumors. Its pipeline includes Galinpepimut-S (GPS), a WT1-targeting cancer immunotherapeutic, and SLS009, a selective CDK9 inhibitor being developed for acute myeloid leukemia (AML) and other hematologic cancers.
Pipeline Update
SLS009 is being evaluated in a Phase 2 trial for newly diagnosed AML, with 28 of 80 patients having been enrolled. The company expects...